Curr Health Sci J, vol. 44, no. 3, 2018

Therapeutic Options in Pregnant Women with Thrombophilia Depending on the Genetic Mutations-a Prospective Study

[Original Paper]

J.G. NACEA(2), I. ROTARU(1), A.M. PATRASCU(3), N. CERNEA(2)


(1)Department of Hematology, University of Medicine and Pharmacy of Craiova, Romania,
(2)Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Histology, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

The aim is to evaluate the effects of anticoagulant therapy (Enoxaparine) compared to antiaggregant therapy (Aspirin) on pregnancy outcome depending on the mutational status of clotting factors. The study was conducted prospectively over a 2 years period and included 110 pregnant women, of whom 80 patients diagnosed with hereditary thrombophilia and 30 healthy pregnant women, representing the control group. After careful observation, we concluded a positive influence of Enoxaparine on pregnancy outcome in pregnant women homozygous carriers for factor V Leiden gene mutation and compound heterozygous for Factor V Leiden and Prothrombin G20210A gene mutation. The study did not find significant positive results in women with heterozygous Factor V Leiden and G20210A prothrombin gene mutation who received anticoagulant therapy as well as pregnant women who received low-dose Aspirin compared with controls.


Keywords:
Thrombophilia, Clexane, Aspirin, pregnancy outcome



Corresponding:
Ionela Rotaru, Department of Hematology, University of Medicine and Pharmacy of Craiova, Petru Rares St. No 2, Craiova, Romania, e-mail: rodirot@yahoo.com


DOI 10.12865/CHSJ.44.03.13 - Download PDF